Abbott Acquires Exact Sciences to Expand Cancer Screening Business
Abbott Acquires Exact Sciences to Expand Cancer Screening Business
On March 23, 2026, healthcare giant Abbott Laboratories finalized its acquisition of Exact Sciences for $21 billion.
This strategic deal marks a major expansion into the $60 billion cancer screening and precision oncology diagnostics market.
By adding Exact Sciences to its portfolio, Abbott aims to build a comprehensive diagnostic ecosystem that covers everything from early detection to monitoring cancer recurrence.
Key products included in the merger are Cologuard, a non-invasive colorectal cancer test, and Oncotype DX, a genomic test for personalized breast cancer treatment.
This acquisition reflects a growing trend in the medical technology industry toward platform consolidation, where companies seek to integrate entire technological ecosystems.
For Abbott, the deal also serves as a critical growth lever, helping to diversify revenue streams following the post-pandemic decline in demand for COVID-19 testing.
